Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Cures' Innovation Fund Targeted At Some Device Provisions In Latest Bill

This article was originally published in The Gray Sheet

Executive Summary

FDA officials could draw from $550 million of a new “Innovation Fund” to implement certain 21st Century Cures legislation device reforms, including a breakthrough device program, health IT reforms and other provisions. The latest version of the bill, which newly directs those funds to device sections, is heading to the House floor this week.

You may also be interested in...

'Cures' Bill Passes, As More Budget, Safety Debates Wait In The Wings

The 21st Century Cures bill passed on a 344-77 vote, attracting significant bipartisan support in the House. It includes multiple provisions supported by the device industry, including a priority review pathway for breakthrough devices. Attention now moves to the Senate, which is working on its own bill that could face budget barriers and calls for more safety protections.

FDA Succession Planning Targeted In Congress As Hamburg Heads For Exit

Margaret Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in the House 21st Century Cures discussion draft would mandate a similar process always be followed.

Octave Biosciences Takes It Up Another Semitone With Michael J Fox Foundation Grant

The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts